Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Associated Therapies
-
Clinical Trials
Related News

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

First Posted Date
2017-01-13
Last Posted Date
2024-08-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
560
Registration Number
NCT03020030
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇨🇦

Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada

and more 6 locations

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

First Posted Date
2017-01-12
Last Posted Date
2017-07-28
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
402
Registration Number
NCT03018626
Locations
🇨🇳

Ru Feng, Guangzhou, Guangdong, China

Paediatric Hepatic International Tumour Trial

First Posted Date
2017-01-11
Last Posted Date
2024-05-13
Lead Sponsor
University of Birmingham
Target Recruit Count
450
Registration Number
NCT03017326
Locations
🇧🇪

Cliniques Universitaires Saint-Luc, Brussels, Woluwe-Saint-Lambert, Belgium

🇮🇪

Children's Health Ireland Crumlin, Dublin, Ireland

🇮🇱

Schneider Children's Medical Center, Petach Tikva, Israel

and more 28 locations

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

First Posted Date
2016-12-28
Last Posted Date
2023-05-22
Lead Sponsor
Celgene
Target Recruit Count
46
Registration Number
NCT03003520
Locations
🇺🇸

Parkview Research Center, Fort Wayne, Indiana, United States

🇦🇹

Hanusch Krankenhaus, Wien, Austria

🇩🇰

Odense Universitetshospital, Odense C, Denmark

and more 17 locations

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

First Posted Date
2016-12-05
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
80
Registration Number
NCT02981628
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 153 locations

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

First Posted Date
2016-11-01
Last Posted Date
2020-03-11
Lead Sponsor
Ruijin Hospital
Target Recruit Count
58
Registration Number
NCT02951728
Locations
🇨🇳

Shanghai Ruijin Hospital, Shanghai, China

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

First Posted Date
2016-09-29
Last Posted Date
2020-01-28
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
100
Registration Number
NCT02918747
Locations
🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

First Posted Date
2016-09-22
Last Posted Date
2024-10-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
12
Registration Number
NCT02911142
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

First Posted Date
2016-09-09
Last Posted Date
2016-09-30
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
500
Registration Number
NCT02894645
Locations
🇲🇾

University of Malaya Medical Centre, Kuala Lumpur, Malaysia

🇲🇾

Subang Jaya Medical Centre, Subang Jaya, Malaysia

🇸🇬

National University Hospital, Singapore, Singapore

and more 1 locations

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

First Posted Date
2016-09-05
Last Posted Date
2024-10-09
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
214
Registration Number
NCT02889523
Locations
🇫🇷

APHP - Hôpital Saint Louis, Paris Cedex 10, France

🇫🇷

Centre Henri Becquerel, Rouen, France

🇫🇷

Institut Gustave Roussy, Villejuif, France

and more 28 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy